By Ben Wylie
In the future, as mRNA technology usage expands, drug manufacturers will have to utilize new approaches to optimize manufacturing efficiency. The speed at which COVID-19 vaccines were developed and produced on a vast scale made the need for efficiency even more prominent, along with an expectation to continue matching that production speed. This aspiration to maximize efficiency should be balanced with the need to ensure compliance to the new Annex 1 guidelines ahead of their implementation. Explore how to pursue the desire for enhanced production efficiency whilst increasing sterility assurance and using single-use technology.